9.72
-0.26(-2.61%)
Currency In USD
| Previous Close | 9.98 |
| Open | 10.08 |
| Day High | 10.08 |
| Day Low | 9.62 |
| 52-Week High | 18.75 |
| 52-Week Low | 8.06 |
| Volume | 39,235 |
| Average Volume | 77,963 |
| Market Cap | 129.94M |
| PE | -7.65 |
| EPS | -1.27 |
| Moving Average 50 Days | 9.87 |
| Moving Average 200 Days | 12.4 |
| Change | -0.26 |
If you invested $1000 in Greenwich LifeSciences, Inc. (GLSI) since IPO date, it would be worth $1,944 as of May 29, 2025 at a share price of $9.72. Whereas If you bought $1000 worth of Greenwich LifeSciences, Inc. (GLSI) shares 3 years ago, it would be worth $1,255.81 as of May 29, 2025 at a share price of $9.72.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
GlobeNewswire Inc.
Apr 02, 2025 10:00 AM GMT
STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immun
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026
GlobeNewswire Inc.
Mar 27, 2025 10:00 AM GMT
STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immun
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01
GlobeNewswire Inc.
Mar 17, 2025 10:45 AM GMT
STAFFORD, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immun